Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, Adam reports back from the nation’s biggest hematology conference on an early but promising gene therapy that could end up being a cure for sickle cell. Then, STAT biotech correspondent Meghana Keshavan joins us to break down the strange case of recently approved drug that has some patients up in arms. Then we give you the need-to-know on Moderna Therapeutics and what its history-making IPO means for the whole drug industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy